| Added by | André Pèlegrin |
|---|---|
| Group name | EquipeAP |
| Item Type | Journal Article |
| Title | [French ccAFU guidelines - Update 2018-2020: Prostate cancer] |
| Creator | Rozet et al. |
| Author | F. Rozet |
| Author | C. Hennequin |
| Author | J.-B. Beauval |
| Author | P. Beuzeboc |
| Author | L. Cormier |
| Author | G. Fromont-Hankard |
| Author | P. Mongiat-Artus |
| Author | G. Ploussard |
| Author | R. Mathieu |
| Author | L. Brureau |
| Author | A. Ouzzane |
| Author | D. Azria |
| Author | I. Brenot-Rossi |
| Author | G. Cancel-Tassin |
| Author | O. Cussenot |
| Author | X. Rebillard |
| Author | T. Lebret |
| Author | R. Renard Penna |
| Author | A. Méjean |
| Abstract | OBJECTIVE: The purpose of the guidelines national committee ccAFU was to propose updated French guidelines for prostate cancer. METHODS: A Medline search was achieved between 2016 and 2018, as regards diagnosis, options of treatment and follow-up of prostate cancer, and to evaluate the different references specifying their levels of evidence. RESULTS: Epidemiology, classification, staging systems, diagnostic evaluation of prostate cancer are reported. Disease management options are detailed. Recommandations are reported according to the different clinical situations. Active surveillance is a major option in low risk PCa. Radical prostatectomy remains a standard of care of localized PCa. The three-dimensional conformal radiotherapy is the technical standard. A dose of?76Gy is recommended. Moderate hypofractionation provides short-term biochemical control comparable to conventional fractionation. In case of intermediate risk PCa, radiotherapy can be combined with short-term androgen deprivation therapy (ADT). In case of high-risk disease, long-term ADT remains the standard of care. ADT is the backbone therapy of metastatic disease. In men with metastases at first presentation, upfront chemotherapy combined with ADT should be considered as a standard. In this situation, the combination of ADT and abiraterone acetate also becomes a new standard. In case of metastatic castration-resistant PCa (mCRPC), new hormonal treatments and chemotherapy provide a better control of tumor progression and increase survival. CONCLUSION: These updated French guidelines will contribute to increase the level of urological care for the diagnosis and treatment for prostate cancer. |
| Publication | Progres En Urologie: Journal De l'Association Francaise D'urologie Et De La Societe Francaise D'urologie |
| Volume | 28 Suppl 1 |
| Pages | R81-R132 |
| Date | Nov 2018 |
| Journal Abbr | Prog. Urol. |
| Language | fre |
| DOI | 10.1016/j.purol.2019.01.007 |
| ISSN | 1166-7087 |
| Short Title | [French ccAFU guidelines - Update 2018-2020 |
| Library Catalog | PubMed |
| Extra | 00000 PMID: 31610875 |
| Tags | Cancer de la prostate, Diagnosis, Diagnostic, Guidelines, nonvisible, Prostate cancer, Recommandations, review, Traitement, Treatment |
| Date Added | 2019/10/21 - 17:08:32 |
| Date Modified | 2019/12/11 - 18:34:25 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
